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Abstract
Background: Increasing evidence suggests that microglial activation may participate in the aetiology and
pathogenesis of Parkinson’s disease (PD). CD200-CD200R signalling has been shown to be critical for restraining
microglial activation. We have previously shown that expression of CD200R in monocyte-derived macrophages,
induced by various stimuli, is impaired in PD patients, implying an intrinsic abnormality of CD200-CD200R
signalling in PD brain. Thus, further in vivo evidence is needed to elucidate the role of malfunction of CD200-
CD200R signalling in the pathogenesis of PD.
Methods: 6-hydroxydopamine (6-OHDA)-lesioned rats were used as an animal model of PD. CD200R-blocking
antibody (BAb) was injected into striatum to block the engagement of CD200 and CD200R. The animals were
divided into three groups, which were treated with 6-OHDA/Veh (PBS), 6-OHDA/CAb (isotype control antibody) or
6-OHDA/BAb, respectively. Rotational tests and immunohistochemistry were employed to evaluate motor deficits
and dopaminergic neurodegeneration in animals from each group. HPLC analysis was used to measure
monoamine levels in striatum. Morphological analysis and quantification of CD11b- (or MHC II-) immunoreactive
cells were performed to investigate microglial activation and possible neuroinflammation in the substantia nigra
(SN). Finally, ELISA was employed to assay protein levels of proinflammatory cytokines.
Results: Compared with 6-OHDA/CAb or 6-OHDA/Veh groups, rats treated with 6-OHDA/BAb showed a significant
increase in counts of contralateral rotation and a significant decrease in TH-immunoreactive (TH-ir) neurons in SN. A
marked decrease in monoamine levels was also detected in 6-OHDA/BAb-treated rats, in comparison to 6-OHDA/
Veh-treated ones. Furthermore, remarkably increased activation of microglia as well as up-regulation of
proinflammatory cytokines was found concomitant with dopaminergic neurodegeneration in 6-OHDA/BAb-treated
rats.
Conclusions: This study shows that deficits in the CD200-CD200R system exacerbate microglial activation and
dopaminergic neurodegeneration in a 6-OHDA-induced rat model of PD. Our results suggest that dysfunction of
CD200-CD200R signalling may be involved in the aetiopathogenesis of PD.
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Parkinson’s disease (PD) is the second most common
neurodegenerative disease in the world, and is character-
ized by dopaminergic neuron loss in the substantia nigra
pars compacta (SNpc) [1]. PD was first described by
James Parkinson in 1817, and the aetiology of PD still
remains unknown. However, emerging investigations
suggest that multiple factors, both genetic and acquired,
contribute to the loss of dopaminergic cells in the sub-
stantia nigra (SN) of these patients [2-4]. Among these
culprits, accumulated evidence suggests that neuroin-
flammation, which is characterised by activation of
microglia and subsequent production of proinflamma-
tory cytokines, may play an important role in the neuro-
degenerative process in PD. Activated microglia are
f o u n di nt h eS No fm e s e n c e p h a l o ni nt h eb r a i no fP D
patients [5-8] and of parkinsonian animal models [9-13].
Molecules related to neuroinflammation, such as tumor
necrosis factor-alpha (TNF-a), IL-6, IL-1b, interferon-
gamma (IFN-g), and superoxide, have been found co-
localized with microglia in brain, and in cerebrospinal
fluid and serum of PD patients as well [6,7,14-22].
Taken together, those previous studies suggest that per-
sistent activation of microglia is dynamically involved in
the disease’s progression.
CD200R, an important inhibitory receptor present on
microglia [23], actively maintains microglia in a quies-
cent state through its interaction with CD200, a trans-
membrane glycoprotein expressed on neurons [24-29].
Recent publications have demonstrated that disruption
of CD200-CD200R engagement can cause abnormal
activation of microglia and consequent pathological
changes. Microglia in CD200-deficient (CD200
-/-)m i c e
exhibit more characteristics of activation [30]. They are
aggregated, less ramified and have shorter glial pro-
cesses, as well as a disordered arrangement and
increased expression of CD11b and CD45. Moreover,
this increased microglial response is substantiated by
enhanced expression of Class II major histocompatibility
complex (MHC II), TNF-a and inducible nitric oxide
synthetase (iNOS) [31]. Thus, CD200
-/- mice display
earlier onset of experimental autoimmune encephalo-
myelitis (EAE) [30]. In addition, preventing CD200-
CD200R interactions with CD200R-blocking antibodies
also induces augmented microglial activation in EAE
rats [32,33]. Conversely, CD200
-/- mice receiving exo-
genous CD200R agonist, including CD200 antigen [34]
or an agonist anti-CD200R antibody [35], are resistant
to the induction of experimental autoimmune uveoreti-
nitis (EAU). All of these findings suggest that decreased
interaction between CD200 and CD200R is related to
increased activation of microglia. Interestingly, decreased
expression of CD200 and CD200R have also been found
in hippocampus and inferior temporal gyrus of patients
suffering from Alzheimer’s disease [36]. Down-regula-
tion of CD200 has also been detected in brain of mul-
tiple sclerosis (MS) patients [37]. These results suggest
that a deficient CD200-CD200R system may be
involved in the progression of various neurological dis-
orders [38,39]. Our previous study revealed altered reg-
ulation of CD200R in monocyte-derived macrophages
from PD patients [40]. We also found that blocking
CD200-CD200R engagement dramatically exacerbates
dopaminergic neurodegeneration in a primary neuron/
microglia co-culture system [41]. Thus, further in vivo
evidence is needed to thoroughly elucidate the role of
malfunction of CD200-CD200R signalling in the patho-
genesis of PD. In the present study, we used a CD200R
blocking antibody to destroy CD200-CD200R engage-
ment in hemiparkinsonian rats, induced by 6-OHDA
injection. We found that the impairment of CD200-
CD200R interaction resulted in increased microglial
activation and corresponding neurodegeneration in this
animal model of PD.
Methods
Materials
Specific monoclonal antibodies against CD200R
(CD200R-blocking antibody, BAb), CD11b, MHC II
and isotype control mouse IgG1 (Control antibody,
CAb) were obtained from Serotec (Indianapolis, IN,
USA). The ELISA kit for rat-TNFa was obtained from
R&D Systems (Minneapolis, MN, USA). The ELISA kit
for rat-IL-6 was purchased from BD (San Diego, CA,
USA). Elite ABC kit and 3,3’-diaminobenzidine tetra-
hydrochloride (DAB) substrate were purchased from
Vector (Vector Laboratories, Burlingame, CA, USA).
The BCA Protein Assay Kit was from Thermo Fisher
Scientific (Rockford, IL, USA). High-performance
liquid chromatography (HPLC)-grade methanol was
obtained from BDH Laboratory (Poole, UK). All other
chemicals were obtained from Sigma-Aldrich (St.
Louis, MO, USA).
Animals
All animal experiments were performed according to the
NIH Guide for the Care and Use of Laboratory Animals
and were approved by the Shanghai Jiao Tong Univer-
sity School of Medicine Animal Care and Use Commit-
tee (2009087). Male Sprague-Dawley rats (10-12 weeks
old, weighing 220-260 g at the start of the experiment)
were provided by the Shanghai Institutes of Biological
Sciences animal house, and were caged in groups of 5
with food and water given ad libitum. The animals were
kept in a temperature-controlled environment at 22 ± 2°
C on a 12:12 light-dark cycle.
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For stereotaxic surgery, rats were anesthetized with an
intraperitoneal injection of pentobarbital (50 mg/kg).
When the animals were deeply anesthetized, they were
placed in a stereotactic apparatus. Subsequently, the rats
were injected with BAb (1 μg/μl, 5 ul for each site) or
CAb (1 μg/μl, 5 ul for each site) into the right striatum
(anterior lesion site: AP: 1.0 mm anterior to the bregma,
L: 2.6 mm from the midline, D: 4.5 mm from the dura;
posterior lesion site: AP: 0.3 mm posterior to the
b r e g m a ,L :3 . 5m mf r o mt h em i d l i n e ,D :4 . 5m mf r o m
the dura). The sham groups were injected with vehicle
(10 mM PBS, 5 μl for each site, Veh). The next day,
each group was injected with 6-OHDA (4 μg/μli n0 . 9 %
saline with 0.02% ascorbic acid, 2 μl for each site) into
the right ascending medial forebrain bundle (MFB) (one
4.2 mm posterior to bregma, 1.2 mm lateral to the mid-
line, and 7.8 mm below the dura, and another 4.4 mm
posterior to bregma, 1.7 mm lateral to the midline, and
7.8 mm below the dura). The microinjection coordinates
used were obtained from a rat brain atlas by Paxinos
and Watson. The injection was made at a rate of 1 μl/
min using a 10 μl Hamilton syringe with a 26-gauge
needle. At the end of each injection, the syringe needle
was left in place for 5 min, and then was slowly with-
drawn to prevent reflux of the solution.
Tissue preparation
At 21 days post 6-OHDA-injection, animals were deeply
anesthetized with pentobarbital (100 mg/kg, i.p.) and
perfused through the aorta with 150 ml of 0.9% saline,
followed by 250 ml of a cold fixative consisting 4% par-
aformaldehyde in 100 mM phosphate buffer (PB). Brains
were then dissected out (3-4 mm in thickness) and post-
fixed for 24 hours with paraformaldehyde in 100 mM
PB before placed into 30% sucrose solution in phos-
phate-buffered saline for 24-72 hours at 4°C. Brains
were then cryosectioned coronally on a Leica1650 cryo-
stat (cut thickness: 25 μm) with a random start, and
including sections before and after both anatomical
regions to confirm the entire structure was quantified.
Sections were collected serially throughout the SN and
placed into PBS for further experiments.
Immunohistochemistry
Free-floating sections were pretreated with 0.3% H2O2 in
0.1 M PBS (pH 7.2-7.5) for 10 min at RT (60 rpm) to
block endogenous peroxidase activity, then washed with
0 . 1MP B Sf o r3t i m e s .T h etissue was then blocked
with diluted blocking serum (Elite ABC kit, Vector
Laboratories, Burlingame, CA, USA) for 20 minutes at
room temperature. Sections were then incubated with
the primary antibody to TH (mouse anti-TH, 1:4000,
Sigma), CD11b (mouse anti-CD11b, 1:1000, serotec) or
MHC II (mouse anti-MHC II, 1:1000, serotec) over-
night at 4°C. The following day the sections were
washed and then incubated with diluted biotinylated
secondary antibody (Vector laboratories) for 30 min at
room temperature. The secondary antibody was ampli-
fied using avidin-biotin complex (Vector laboratories)
for 30 min at room temperature. Finally the sections
were developed with 3,3’-diaminobenzidine tetra-
hydrochloride (Vector Laboratories). Sections were
then mounted onto glass slides and dried overnight.
The next day the slides were passed through a gradient
of ethyl alcohol and xylene to dehydrate the tissue.
The slides were then coverslipped using permount
mounting medium.
Cell quantification
Unbiased stereological estimates of DA (TH-positive
cell) neuron numbers were performed using StereoIn-
vestigator analysis software (MicroBrightField, Williston,
VT), combined with a Nikon Eclipse E600 microscope,
and the optical fractionator method according to pre-
viously published reports [42,43]. Boundaries in the SN
were defined according to previously defined anatomical
analysis in the rat [44] and cells were counted from
every sixth 25-μm section (~24 sections) along the
entire SN (to ensure coefficient of errors <0.1, the ros-
tral-caudal length of the SN was 4 mm), by investigators
blinded to treatment history, with a 60 × objective. In
brief, optical dissectors (area of counting frame, 64,000
mm
3;g u a r dh e i g h t ,2μm; spaced 300 μm apart in the
x-direction, and 200 μm apart in the y-direction) were
applied to each section in the series throughout the
entire SN (including pars reticulata and compacta; esti-
mates are reflective of two sides; n = 5 for each group).
We show the percent of neurons remaining on the ipsi-
lateral side compared to those on the intact contralateral
side. Values are expressed as the mean ± S.E.M. of all
animals in each group.
Microglial quantification similarly used adjacent (8
sections) serial sections. An observer blind to sample
identity counted numbers of CD11b-immunoreactive
(CD11b-ir) positive cells in the SN on each side (Nikon
microscope at a 40 × magnification). Here the X-Y step
length used was between 300-400 mm in order to count
100-200 CD11b-ir cells in each side of the SN. A posi-
tive cell was defined as a nucleus covered and sur-
rounded by CD11b immunostaining. The stage of cells
was identified by their morphology. For quantitation of
MHC II immunoreactive (MHC II-ir) cells, cells in stage
4 were identified by their morphology on MHC II stain-
ing under 40× magnification and counted in every sixth
25-μm-thick serial section of the SN of each rat using a
two-blinded procedure. Graphs show the number of
MHC II-ir cells in the SN.
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Animals (n = 5 each of the following groups: 6-OHDA/
Veh, 6-OHDA/CAb, and 6-OHDA/BAb) were sacrificed
by CO2 and their brains were quickly removed and
placed on ice. The left and right striatum were freshly
dissected out, weighed, frozen in liquid nitrogen, and
stored at -80ºC for later use.
Each sample was homogenized by sonication in ice-
cold 0.1 mol/L perchloric acid and then centrifuged at
12,000 rpm for 30 minutes at 4ºC. The supernatants (20
μl) were injected into a high-performance liquid chro-
matography (HPLC) system coupled to an electrochemi-
cal detection device (Coularray; ESA, Chelmsford, MA)
for measuring dopamine (DA), 3,4-dihydroxyphenylace-
tic acid (DOPAC) and homovanillic acid (HVA). The
protein contents were determined in pellet fractions by
the method described by Lowry [45], and expressed as
ng/g wet weight of tissue (ng/g WW).
Classification of microglial activation
We adapted a classification system for microglial activa-
tion according to Kreutzberg [46]:
Stage 1: Resting microglia. Rod-shaped soma with fine
and ramified processes.
Stage 2: Activated ramified microglia. Elongated cell
body with long and thicker processes.
Stage 3: Amoeboid microglia. Round body with short,
thick and stout processes.
Stage 4: Phagocytic cells. Round cells with vacuolated
cytoplasm; no processes can be observed at the light
microscopy level.
Stages of microglia activation were confirmed by
observation by at least two blinded observers. Black cir-
cles in Figure 2 show examples of microglia in different
stages. All of these cell types are CD11b-ir, and MHC II
stained only activated microglia but not resting
microglia.
Rotational behaviour
Apomorphine-induced rotational behaviour was assessed
at 7 and 21 days after 6-OHDA-injection. Rotational
behaviour was tested in rotometer bowls [47]. Five min-
utes after intraperitoneal administration of apomorphine
(0.5 mg/kg diluted in 0.9% saline), the total number of
full 360° rotations in the contralateral direction was
counted for 30 min.
ELISA for TNF-a and IL-6
Rats were killed by CO2 overdose followed by cervical
dislocation and decapitation at 21 days after injection
of 6-OHDA. The brain was removed and immediately
transferred to ice and cut at the level of the infundibu-
lar stem forming a hindbrain block containing the SN.
The SN were dissected, snap-frozen in liquid nitrogen
a n ds t o r e da t- 8 0 ° C .T i s s u ew a sh o m o g e n i z e do ni c ei n
400 μlo fT r i s - H C lb u f f e r( p H=7 . 3 )c o n t a i n i n gp r o -
tease inhibitors (10 mg/ml aprotinin, 5 mg/ml peptas-
tin, 5 mg/ml leupeptin, 1 mM PMSF). Homogenates
were centrifuged at 10,000 g at 4ºC for 10 min and
then ultracentrifuged at 40,000 r.p.m. for 2 h. Superna-
tants were aliquoted and stored at -80ºC until use.
BCA protein assays were performed to determine total
protein concentration in each sample. Commercially
available rat TNF-a (R&D, Minneapolis, MN, USA and
rat IL-6 kits (BD, San Diego, CA, USA) with high sen-
sitivity were used to quantify these cytokines according
to the manufacturers’ instructions (7.8 pg/ml for
rTNF-a and 20 pg/ml for rIL-6). Three animals per
group were analyzed and each sample was analyzed in
duplicate.
Statistical analysis
Statistical analysis of the data was performed using
GraphPad Prism version 5.00 for Windows (GraphPad
Software, San Diego California, USA, http://www.graph-
pad.com). The results are reported as mean ± SEM.
T w o - w a yA N O V Af o l l o w e db yB o n f e r r o n i ’st e s tw a s
applied to determine significant differences among data
of rotational experiments with two time points. Univari-
ate one-way ANOVA and Tukey-Kramer post-hoc test
were used to analyze data from other experiments
between treated groups. The criterion for statistical sig-
nificance was P < 0.05.
Results
BAb administration enhances rotational asymmetry in 6-
OHDA-induced hemiparkinsonian rats
Unilateral injection of 6-OHDA into medial forebrain
bundle (MFB) induces the loss of dopaminergic cell in
the ipsilateral SNpc and was used as a hemiparkinso-
nian animal model in this study. To investigate the
role of CD200-CD200R dysfunction in 6-OHDA-
induced neurotoxicity, we employed a CD200R mono-
clonal antibody to block CD200-CD200R engagement,
which was first used by Wright, G. J. [32], and later by
many other investigators [33,41,48-51]. In the present
study, BAb, CAb or Veh was injected into striatum
one day before 6-OHDA injection. Then, apomor-
phine-induced rotational behaviour was analyzed to
assess unilateral degeneration of presynaptic dopami-
nergic neuron terminals at 7 and 21 days after 6-
OHDA injection. Although rats that had been microin-
jected with 6-OHDA/Veh could contralaterally rotate
t ot h es i t eo f6 - O H D Al e s i o nw i t ha p o m o r p h i n e
administration (1.5 ± 0.6 at 7 days, 3.7 ± 1.3 at 21
days), apomorphine-induced rotation was significantly
increased in 6-OHDA/BAb rats at both time points
(7.7 ± 2.6 and 18.3 ± 2.3 respectively, p < 0.0001)
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bated but also accelerated (as early as 7 days) motor
deficits in hemiparkinsonian rats (Figure 1). Animals
that responded to apomorphine treatment with at least
7.0 turns/min could be regarded as successfully
induced hemiparkinsonian rats [43,52]. The rats that
received 6-OHDA/Veh treatment showed only 1.5 ±0.6
turns/min at 7 days and 3.7 ±1.3 turns/min at 21 days
induced by apomorphine administration, and both of
these values are less than 7.0 turns/min. So the dose of
6-OHDA (16 μg) used in this experiment could be
considered as a sub-toxic dose. However, rats treated
with 6-OHDA/CAb did not show a significant increase
in contralateral rotational number, 2.7 ± 1.1 turns/min
at 7 days and 4.7 ±1.7 turns/min at 21 days, compared
to the rats treated with 6-OHDA/Veh (Figure 1).
BAb administration exacerbates 6-OHDA-induced
neurodegeneration
To confirm that the phenotype of our PD rats is consis-
tent with dopaminergic neuron loss in SN, we stained
midbrain coronal sections with an antibody against tyro-
sine hydroxylase (TH) and performed non-biased stereo-
logical estimation of TH-immunoreactive (TH-ir)
neurons in SN. We observed that a sub-toxic dose of
6 - O H D Aw a sa b l et oi n d u c em o d e r a t eb u tn o to v e r t
dopaminergic neurodegeneration in SN (55.0 ± 6.0% of
contralateral) (Figure 2A). Intrastriatal injection of BAb
resulted in a significant decrease in TH-ir neurons in
whole SN in animals treated with 6-OHDA/BAb (5.2
±2.0%, P < 0.0001). However, no dramatic decrease in
TH-ir cells was observed between groups treated with
6-OHDA/Veh and 6-OHDA/CAb (Figure 2A). These
results indicate an exacerbating effect of BAb on the
degeneration of dopaminergic neurons. At higher mag-
nifications, we observed that treatment of 6-OHDA/BAb
not only decreased the number of TH-ir cells but also
their arborisation or fibers. TH-ir fibers (Figure 2 arrow-
heads) were less densely spread amongst TH-ir cell
bodies (Figure 2 arrows) in the SN in 6-OHDA/BAb-
treated rats (Figure 2G), compared to either control
group (6-OHDA/Veh, 6-OHDA/CAb) (Figure 2E-F).
There were no marked morphological differences in
numbers of TH-ir cells in SN between rats pretreated
with CAb (6-OHDA/CAb) and Veh (6-OHDA/Veh)
(Figure 2E-F). Furthermore, BAb administration had a
significant effect on DA and its metabolites in ipsilateral
striatum. Twenty-one days after 6-OHDA injection, the
DA content of right striatum in 6-OHDA/Veh-treated
rats was 1765 ± 236 ng/g wet weight of tissue (ng/g
WW) (n = 5) (Table 1). Protein levels of DA metabolites
in this group were 894 ± 95 ng/g WW (n = 5) and 599
± 104 ng/g WW (n = 5) for DOPAC and HVA respec-
tively (Table 1). Injection of CAb prior to 6-OHDA-
lesion did not cause significant changes in DA or its
metabolites in the right striatum of rats in comparison
to vehicle control animals (Table 1), while the contents
of DA and its metabolites in 6-OHDA/BAb group were
significantly lower than that in the 6-OHDA/Veh group.
These values were 38 ± 8 ng/g WW (n = 5), 24 ±3 ng/g
WW(n = 5) and 17 ±2 ng/g WW (n = 5), respectively
(Table 1).
BAb treatment exacerbates 6-OHDA-induced microglial
activation
The direct effect of BAb is destruction of the balance
between CD200 and its receptor. CD200R receptor is
expressed only on microglia [24,53,54].
Signal transferred from CD200 to its only known
receptor, CD200R, has been shown to be critical for
restraining microglial activation [30]. Thus, we studied
Figure 1 BAb exacerbates 6-OHDA-induced behavioural
deficits. Contralateral rotation measurements following
administration of apomorphine in each experimental group are
shown in bar graph at 7 days and 21 days post-6-OHDA injection.
Data are presented as mean ±S.E.M (n = 5 rats/group). (#)Statistical
differences from 6-OHDA/Veh- or 6-OHDA/CAb-treated animals are
P < 0.001.
Zhang et al. Journal of Neuroinflammation 2011, 8:154
http://www.jneuroinflammation.com/content/8/1/154
Page 5 of 12microglial activation and possible neuroinflammation in
SN at 21 days post-6-OHDA-injection by immunohisto-
chemistry as described in Methods.
First, we studied morphological changes and quantifi-
cation of microglia using the microglia-specific marker
CD11b (a constitutive marker of microglia). CD11b
recognizes complement receptor type 3 (CR3), the
expression of which is greatly increased in hyperactive
microglia compared with resting microglia. In our study,
profound microglial responses were observed in ipsilat-
eral SN in rats following treatment with 6-OHDA/BAb
(Figure 3F,I). Round and amoeboid cells (Stage 4)
became predominant in the core of the SN and were
mingled with rod-shaped (stage 3) or highly ramified
(stage 2) microglia near the boundary (Figure 3I).
Twenty one days post-6-OHDA injection there was an
increase in CD11b-ir cells in all groups. In addition, we
found that the total number of CD11b-ir cells in SN
Figure 2 Neurodegeneration is exacerbated in the SN of hemi-parkinsonian rats. Animals (5 rats per groups) were sacrificed at 21-day post
6-OHDA injection to characterize and quantify loss of dopaminergic neurons in whole SN. (B-G) Representative sections (~24 sections per rat) of
SN were immunostained with antibodies against tyrosine hydroxylase (TH). (B,E) SN of 6-OHDA/Veh group, (C,F) SN of 6-OHDA/CAb group, (D,G)
SN of 6-OHDA/BAb group. The bottom photos (E-G) are higher magnifications of the cells in black rectangles of ipsilateral SN in the upper
photos (B-D). Scale bar: 1 mm (B-D); scale bar: 50 μm (E-G). Arrows: neurons; arrowheads: fibers. (A) Stereological cell counts of total TH-ir
neurons on the ipsilateral side of the SN are shown as a percentage of the cells on the contralateral side (n = 5/group, # P < 0.0001). All the
results were obtained in a two-blinded procedure. No significant difference was found between the group treated with 6-OHDA/Veh and the
group treated with 6-OHDA/CAb (P = 0.5108). Data are presented as mean ± S.E.M.
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(716 ± 23%, P = 0.0002) versus 6-OHDA/CAb-treated
rats (318 ± 20%) and 6-OHDA/Veh-treated rats (273 ±
27%) (Figure 3A). No significant difference was found
between 6-OHDA/Veh and 6-OHDA/CAb groups (P =
0.2519) (Figure 3A). Furthermore, we analysed the quan-
tification of microglia in different stages. Four cellular
patterns (Figure 1, 2, 3, 4) were defined according to
Kreutzberg’s classification [46]. We observed that stage
4 cells constituted over 85% of the microglia population
in the 6-OHDA/BAb-treated group, while less than 10%
of them were found in the other two groups (Figure
3B). The majority of cells presenting in the core lesion
of the SN in the other two groups were stage 3 cells or
stage 2 cells. In the 6-OHDA/Veh group, stage 3 cells
constituted about 34% of the population, while 39% of
population turned out to be stage 2 cells. In the 6-
OHDA/CAb group, 33% of population were stage 3
cells, while 38% were stage 2 cells. Statistically signifi-
cant differences were found between the 6-OHDA/BAb-
treated group and the two control groups (P < 0.01),
but no difference was found between the two control
groups. We also investigated the expression of MHC II,
a marker for activated microglia, which is practically
undetectable in resting microglia. MHC II-ir cells
showed similar morphology to that of stage 4 microglia.
MHC II-ir microglia were found scattered throughout
the SN in the 6-OHDA/Veh and 6-OHDA/CAb groups
(Figure 3M-N), while mainly stage 4 MHC II-ir micro-
glia were visualized in the core lesion of SN from the 6-
OHDA/BAb treated group (Figure 3L,O). The number
of stage 4 MHC II-ir microglia was dramatically
increased in 6-OHDA/BAb-treated rats compared with
the two control groups (n = 5, P < 0.001) (Figure 3C).
No difference was detected between the two control
groups.
Taken together, these data suggest that BAb adminis-
tration shifts stage 2 or stage 3 microglia to stage 4 in
SN. These results also show a distinct population of
activated microglia (MHC II-ir), which correlates with
levels of neurodegeneration and motor deficit in the 6-
OHDA/BAb group.
BAb treatment increases 6-OHDA-induced
proinflammatory factors production in SN
To further confirm a relationship between CD200-
CD200R signalling and neuroinflammation in PD, we
assayed several molecules that would be secreted by
activated microglia in the proinflammatory stage
[10,55-59]. We detected the expression profile of two
most-important cytokines, TNF-a and IL-6, in SN of
rats from each group at 21 days post-6-OHDA-injection.
This is the time point at which dopaminergic neurode-
generation, rotational behaviour and microglial activa-
tion were investigated. Interestingly, we found
significant increases in the induction of TNF-a and IL-6
expression in rats treated with 6-OHDA/BAb in com-
parison with the other treatments (6-OHDA/CAb, 6-
OHDA/Veh) (Figure 4, P < 0.001). No difference was
noted between the two control groups (Figure 4). Thus
we speculate that these two cytokines, TNF-a and IL-6,
might be involved in the exacerbating effects observed
in the 6-OHDA/BAb-treated animals.
Discussion
We sought in vivo evidence for a role for CD200-
CD200R dysfunction in the etiopathogenesis of PD.
Microglia, which are not only the resident innate
immune cells in the CNS [23,46] but also the predomi-
nant cells that express CD200R in CNS [60], play a criti-
cal role in maintaining a homeostatic milieu for most
vulnerable dopaminergic neurons. CD200-CD200R sig-
nalling is considered to be a brake on innate immunity
[61]. Breaking the interaction between CD200 and
CD200R will cause abnormal activation of microglia in
brain.
Normal CD200-CD200R signalling maintains micro-
glia in a quiescent state. Hoek et al. [30] first reported
that disruption of CD200-CD200R interaction in the
nervous system can cause EAE, which is related to
abnormal activation of microglia. Recently, several stu-
dies have shown links between CD200/CD200R signal-
ling and PD, Alzheimer’s disease (AD) and prion
diseases. Protein and mRNA levels of CD200 and
CD200R are decreased in hippocampus and inferior
Table 1 BAb administration increases 6-OHDA-induced dopamine deficiency in ipsilateral striatum.
Groups Content (ng/g Wet weight of tissue)
DA DOPAC HVA
6-OHDA/Veh 1765.0 ± 235.6 894.1 ± 94.7 598.8 ± 103.6
6-OHDA/CAb 1674.0 ± 174.9 836.7 ± 72.3 551.7 ± 121.5
6-OHDA/BAb 37.6 ± 7.8 *** 24.2 ± 3.2 *** 16.7 ± 2.3 **
**p < 0.01, ***p < 0.001 compared to the 6-OHDA/Veh and 6-OHDA/CAb groups (n = 5 per group)
Results are expressed as mean ± S.E.M. (ng/g WW) of total protein. Data are shown only for ipsilateral (right) side of striatum. Statistical analysis was performed
by two-way ANOVA. ** p < 0.01, *** p < 0.001 as compared to 6-OHDA/Veh lesion group.
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Page 7 of 12Figure 3 Effects of BAb on microglial morphology and cell number in SN. Representative sections of SN in different groups were
immunostained with antibodies against CD11b (a microglia marker) (D-I) and MHC II (a marker for activated microglia) (J-O) 21 days after 6-
OHDA-injection. G-I and M-O are higher magnifications of the fields outlined by rectangles in D-F and J-L respectively. Scale bar: 500 μm in D-F
and J-L; scale bar: 50 μm in G-I and M-O. Representative microglia in different stages (stage1-4) of CD11b immunostaining are shown in yellow
circles (stage1: P1; stage2: P2; stage3: P3; stage4: P4), and a representative of stage 4 MHC II-ir microglia is shown in panel Q. Scale bar:10 μmi n
P1-P4 and Q. Microglia cell numbers and morphology were stereologically analyzed in each group. (A) Data represents average increase of
CD11b-ir microglia cell number in ipsilateral SN as compared to contralateral SN (n = 5) ± S.E.M. #:P < 0.001. (B) Stereological quantification of
each stage of CD11b-ir microglia is depicted as the average percentage distribution per group. # p < 0.001 compared to every other group.
(C) Stereological quantification of stage 4 MHC II-ir cells throughout the SN from different experimental groups is shown in bar graph; n = 5,
value = mean ± S.E.M. #: P < 0.001 significant difference compared to every other group.
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Page 8 of 12temporal gyrus of AD patients [36], suggesting that defi-
ciency of the CD200-CD200R signalling may play an
important role in the progress of AD [36]. Costello et al.
[62] observed an exaggeration of proinflammatory cyto-
kine production, including IL-1b,I L - 6a n dT N F - a,p r o -
duced by CD200
-/- glia And these up-regulated
cytokines correlated with significantly reduced long-
term potentiation (LTP) at CA1 synapses of hippocam-
pal slices from CD200
-/- mice [62]. These findings indi-
cated that loss of CD200-CD200R interaction might
impair synaptic function in hippocampus and play an
important role in dementia. A deficit of CD200-CD200R
has also been found in PD patients. Luo et al. [40]
examined CD200R expression and regulation in mono-
cyte-derived macrophages (MDMs), the peripheral coun-
terpart of microglia, in PD patients and in old and
young healthy controls. They found that basal CD200R
expression is similar in MDMs from young control, old
control and PD patients; however, expression of
CD200R in MDMs induced by various stimuli is
impaired in the older groups, especially in PD patients,
implying an intrinsic abnormality of CD200-CD200R
signalling in PD brain. Interestingly, CD200R expressed
in human beings and rats functions only as an inhibitory
signal [60]. However there are two different CD200Rs in
mice [54,60,63,64]; an inhibitory receptor CD200R1
[48,65-68] and an activating receptor CD200R2-4 [69].
There is no report about the expression levels of
CD200R or CD200 in patients with prion disease, but
activated microglia are thought to be related to up-
regulation of CD200R4 in a mouse model of prion dis-
ease [70]. All of these findings suggest that CD200-
CD200R signalling plays an important role in the patho-
genesis of neurological disorders, including PD.
Previously, we always used 32μgo f6 - O H D At oy i e l d
an animal model of PD [43,52]. This amount would
result in the demise of almost all dopaminergic neurons
in the SN (>95%) and in the ventral tegmental area
(VTA) (>80%) at 3 weeks post-lesion [43,52]. To investi-
gate whether abnormal CD200-CD200R signalling could
exacerbate microglial activation and dopaminergic neu-
rodegneration in the 6-OHDA-induced rat PD model,
we needed to find a proper dose of 6-OHDA that would
produce only a limited loss of TH-ir neurons on the
ipsilateral side of the SN. Therefore, we injected differ-
ent amounts (32μg, 24μg, 16μg, 8μg) of 6-OHDA into
MFB and found that 16μg of 6-OHDA was able to
induce moderate but not overt dopaminergic neurode-
generation in SN (data not shown). This is the sub-toxic
dose of 6-OHDA that is similar to that used by Saucer
H et al. [71], Depino AM et al. [12] and Roedter A et al.
[72]. In these studies, 20μg6 - O H D Ai nt h es t r i a t u m
provoked a moderate and progressive loss of dopaminer-
gic cells in the ipsilateral SN at 3 weeks post -lesion.
The typical phenotype and corresponding neurodegen-
eration, as well as augmented microglial activation,
observed in 6-OHDA/BAb-treated rats suggests that
abnormal CD200-CD200R signalling exacerbates micro-
glial activation and plays an important role in progres-
sion of the disease. It is believed that multiple factors
are involved in the development of PD. Our present
study in a PD rat model and our previous study in PD
patients indicate that both intrinsic abnormal CD200-
CD200R signalling and environmental neurotoxins parti-
cipate in the pathogenesis of PD.
According to previous studies, the bolus administra-
tion of any substance into cerebrum may cause mechan-
ical damage to neurons [73,74] and subsequent adjacent
activation of microglia [74-79]. This makes it difficult to
distinguish activation of microglia caused by injection
from that caused by changes in CD200-CD200R signal-
ling. Beside this, the small volume of the SN makes it
hard to inject any reagent precisely into the SN [80,81].
Finding an ideal alternative antibody injection site
would help to elucidate the role of CD200-CD200R sig-
nalling in the pathogenesis of PD. Phaseolus vulgaris-
leucoagglutinin and biocytin, injected into striatum, can
later be found in substantia nigra pars reticulate (SNpr)
and substantia nigra pars compacta (SNpc) in squirrel
monkeys [82]. In addition, Mufson et al [83] have
shown that intrastriatral infusion of the tracer fluoro-
gold results in transport into the SNpc. The above evi-
dence indicates that antibody injected into striatum may
spread into the SN, causing abnormal activation of
Figure 4 BAb regulates pro-inflammatory factor production in
SN. Concentrations of TNF-a and IL-6 in SN were assayed using
ELISA at 21 days post-6-OHDA injection. Values are shown as mean
± S.E.M. The concentrations of cytokines in the 6-OHDA/BAb co-
treated group were significantly higher than those in the other
groups. There was no significant difference between the 6-OHDA/
CAb- and the 6-OHDA/Veh-treated groups. Data are representative
of three individual experiments. # P < 0.001, significant difference
compared to every other group.
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Page 9 of 12microglia and damage to dopaminergic neurons. Histo-
logical and immunological examinations in rats con-
firmed our speculation. Furthermore, the reduced levels
of DA and its metabolites caused by injection of BAb in
striatum demonstrates impairment of dopaminergic neu-
rons in SN.
The results of this study provide in vivo evidence that
impairment of CD200-CD200R signalling might play an
important role in the pathogenesis of PD. However, our
s t u d yl a c k e dat i m ec o u r s eo fm i c r o g l i a la c t i v a t i o na n d
neuroinflammation. Therefore, further study is required
to fully elucidate the mechanism involved in microglial
activation and subsequent neurodegeneration.
Conclusions
Taking all of these results together, this study shows
that disruption of CD200-CD200R signalling might play
a role in the pathogenesis of PD. The role of CD200-
CD200R signalling in the pathogenesis of PD makes it a
potential therapeutic target for PD therapy. Therapeutic
agents that can efficiently inhibit microglial activation
through regulation of CD200-CD200R signalling may
become a novel approach to the clinical treatment of
PD.
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